Godmanchester PE29 2XG
Situated on a new industrial park next to A14 with other high tech users including CDT, pharmaceutical companies and healthcare multinationals (Smith and Nephew). Cambridge 15 miles via upgraded A14.
Offered as a single unit of 10,000 sq ft. or as one or two separate units of 5,000 sq ft.
Units can be separated into two separate 5,000 sq ft units.
Dry labs
Wet labs
Fume Hoods
Office areas
Production suites (air conditioned, filtered air with option of low RH (5% RH) rooms)
Upgraded electrical supplies and RO water supplies to lab areas
Currently registered…
Researchers at the Cira Foundation (Kyoto, Japan) have published an informative study** that highlights how defined culture conditions using Amsbio StemFit™ Basic03 medium coupled with a supportive matrix (iMatrix-511) contribute to controlling hiPSC behaviour and differentiation efficiency.
The study presents data showing how the choice of iPSC pre-culture medium and extracellular matrix influences the ability of human induced pluripotent stem cells (hiPSCs) to differentiate into cardiac tissues. In the described experiments - researchers compared…
LONDON, UK – January 20, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for mOm Incubators Ltd (“mOm”) and is pleased to announce the placement of Daniel Green as Chief Operating Officer (COO).mOm is a pioneering UK-based health-tech company dedicated to transforming neonatal care. Its flagship product, the mOm Essential Incubator, is a world-first, lightweight, and portable device designed to maintain newborn body temperature in any setting – from modern NHS…
Researchers' expectations of antibodies are changing—from "whether they can be used" to "whether they are stable enough, easy to engineer, and truly meet research needs."Compared with the traditional animal-derived antibody production, recombinant antibodies offer researchers a more controllable technical route. Through molecular cloning and in vitro expression systems, the sequence of the antibody can be precisely defined at the design stage, avoiding common batch-to-batch variations inherent in animal immunization. In response to these research demands, Creative Biolabs has established a…
Creative Biolabs, a USA-based biotechnology company specializing in iPSC research, is delighted to announce its advances in iPSC services.Rare and valuable cell cultures, such as induced pluripotent stem cells (iPSCs), have moved from being an interesting concept to a tool useful for understanding diseases in the last decade. As it took many years or access to scarce patients for understanding diseases in animal models, now cells that matter can be easily derived right from the biologically important individual of choice. As more and more laboratories start adopting iPSC technologies, in this…
LONDON, UK and CAMBRIDGE, MA – January 13, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO).Trevi Therapeutics is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF…
Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British Business Bank, and GK Goh
The funding will accelerate development of eProtein Discovery for full-format antibody expression, purification, and binding validation
Cambridge, UK, and Boston MA, USA, 13 January 2026: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced a USD $12 million financing extension, bringing the Company’s total Series C…
Oversubscribed £2.5M seed round led by Ahren Innovation Capital
Strategic collaboration with o2h to progress drug discovery programme
Cambridge, UK, 12 January 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5M seed funding round. The Company also announced the signing of a strategic agreement with o2h discovery, a preclinical Contract Research Organisation with an integrated drug discovery platform. The partnership aims to launch a collaborative drug discovery programme…
Amsbio announces a new range of well characterized Adeno-Associated Virus (AAV) reference standards that enable researchers to significantly improve their AAV production processes.
Adeno-associated virus can be engineered to transport DNA of interest to target cells, without any viral genes - making them a highly desirable and safe tool for gene therapy. However, one of the greatest challenges in AAV production is that AAV preparations contain a considerable number of viral particles without gene payloads. Even after purification procedures, samples include empty capsids. In gene therapy…
Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operations
Cambridge, UK, 12 January 2026 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Rebecca Simmons as Chief Operating Officer.
Rebecca will be responsible for scaling the Company’s global business operations and leading sustainable growth…